Pay in 4 interest-free payments of $6.88 Learn more
Ships within 48 hours · Estimated delivery Oct 11 - Oct 16
The evidence cited includes the patent's listing in the FDA Orange Book, public statements by Hims's CEO on an August 2024 investor call discussing GLP-1 patent cliffs and acknowledging that semaglutide was not going off patent, and a formal demand letter sent by Novo Nordisk on February 8, 2026, one day before filing
Pharmaceutical GLP1 patches under development: aim to deliver a real GLP1 receptor agonist (such as exendin4 or semaglutide) using microneedle or advanced transdermal technologies, but these remain in preclinical or very early development stages and are not available as approved products
Although these levels fluctuate throughout the day, they are most impacted by food and how often we eat
GLP-Pro can be taken alongside GLP-Activate
Important: This product is supplied strictly for laboratory research use only and is not for human consumption.
